1. Home
  2. RFI vs CAPR Comparison

RFI vs CAPR Comparison

Compare RFI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Total Return Realty Fund Inc.

RFI

Cohen & Steers Total Return Realty Fund Inc.

HOLD

Current Price

$11.15

Market Cap

298.5M

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.56

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFI
CAPR
Founded
1992
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.5M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RFI
CAPR
Price
$11.15
$28.56
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$36.71
AVG Volume (30 Days)
69.8K
5.9M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
8.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,130,509.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,736.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.62
$4.30
52 Week High
$12.52
$40.37

Technical Indicators

Market Signals
Indicator
RFI
CAPR
Relative Strength Index (RSI) 36.67 81.16
Support Level $11.06 $4.30
Resistance Level $11.46 $40.37
Average True Range (ATR) 0.13 2.94
MACD 0.00 2.74
Stochastic Oscillator 20.25 67.59

Price Performance

Historical Comparison
RFI
CAPR

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: